Outcomes in RBC transfusion‐dependent patients with L ow‐/ I ntermediate‐1‐risk myelodysplastic syndromes with isolated deletion 5q treated with lenalidomide: a subset analysis from the MDS ‐004 study-Reference-Cited by-同舟云学术

Outcomes in RBC transfusion‐dependent patients with L ow‐/ I ntermediate‐1‐risk myelodysplastic syndromes with isolated deletion 5q treated with lenalidomide: a subset analysis from the MDS ‐004 study

Published:2014-06-09 Issue:5 Volume:93 Page:429-438
ISSN:0902-4441
Container-title:European Journal of Haematology
language:en
Short-container-title:Eur J Haematol

Author:

Giagounidis Aristoteles¹,Mufti Ghulam J.²,Mittelman Moshe³,Sanz Guillermo⁴,Platzbecker Uwe⁵,Muus Petra⁶,Selleslag Dominik⁷,Beyne‐Rauzy Odile⁸,Boekhorst Peter⁹,Cañizo Consuelo¹⁰,Guerci‐Bresler Agnès¹¹,Nilsson Lars¹²,Lübbert Michael¹³,Quesnel Bruno¹⁴,Ganser Arnold¹⁵,Bowen David¹⁶,Schlegelberger Brigitte¹⁷,Göhring Gudrun¹⁷,Fu Tommy¹⁸,Benettaib Bouchra¹⁸,Hellström‐Lindberg Eva¹⁹,Fenaux Pierre²⁰

Affiliation:

1. Marien Hospital Düsseldorf Düsseldorf Germany

2. King's College Hospital London UK

3. Tel Aviv Sourasky Medical Center Tel Aviv Israel

4. Hospital Universitario y Politécnico La Fe Valencia Spain

5. Medical Clinic and Polyclinic I University Hospital Technical University Dresden Dresden Germany

6. Radboud University Medical Centre Nijmegen The Netherlands

7. AZ St‐Jan Brugge AV Brugge Belgium

8. Centre Hospitalier Universitaire Purpan Pavillion de Médecines Toulouse France

9. Erasmus Medical Center Rotterdam The Netherlands

10. Hospital Universitario de Salamanca Salamanca Spain

11. CHU Brabois University Center of Medicine Vandoeuvre France

12. Skåne University Hospital Lund Sweden

13. University of Freiburg Medical Center Freiburg Germany

14. Centre Hospitalier Régional Universitaire Claude Huriez Service des Maladies du Sang Lille France

15. Hannover Medical School Hannover Germany

16. St James's Institute of Oncology Leeds UK

17. Institute of Cell and Molecular Pathology Hannover Medical School Hannover Germany

18. Celgene Corporation Summit NJ USA

19. Karolinska University Hospital Stockholm Sweden

20. Service d'Hématologie Séniors Hôpital St Louis Université Paris 7 Paris France

Publisher

Wiley

Subject

Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ejh.12380

Reference15 articles.

1. World Health Organization classification in combination with cytogenetic markers improves the prognostic stratification of patients with de novo primary myelodysplastic syndromes

2. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients

3. New Comprehensive Cytogenetic Scoring System for Primary Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia After MDS Derived From an International Database Merge

4. Identification of novel cytogenetic markers with prognostic significance in a series of 968 patients with primary myelodysplastic syndromes;Solé F;Haematologica,2005

5. Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): A multicenter study

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Determinants of lenalidomide response with or without erythropoiesis-stimulating agents in myelodysplastic syndromes: the HOVON89 trial;Leukemia;2024-01-31

2. TP53 variant allele frequency and therapy‐related setting independently predict survival in myelodysplastic syndromes with del(5q);British Journal of Haematology;2023-12-11

3. Cytogenetic peripheral blood monitoring in azacitidine treated patients with high-risk MDS/sAML: A monocentric real-world experience;Leukemia Research;2023-01

4. Practical aspects of the use of erythropoiesis-stimulating agent in patients with hematological malignancy;Meditsinskiy sovet = Medical Council;2022-10-06

5. Impact of Lenalidomide Treatment on Overall Survival in Patients With Lower-Risk, Transfusion-Dependent Myelodysplastic Syndromes;Clinical Lymphoma Myeloma and Leukemia;2022-09